TPCA-1
SIGMA/T1452 - ≥95% (HPLC)
Synonym: [5-
CAS Number: 507475-17-4
Empirical Formula (Hill Notation): C12H10FN3O2S
Molecular Weight: 279.29
MDL Number: MFCD09037541
Linear Formula: C12H10FN3O2S
Product Type: Chemical
| assay | ≥95% (HPLC) |
| color | white to light brown |
| form | powder |
| InChI | 1S/C12H10FN3O2S/c13-7-3-1 |
| InChI key | SAYGKHKXGCPTLX-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100  |
| SMILES string | NC(=O)Nc1sc(cc1C(N)=O)-c2 |
| solubility | DMSO: 5 mg/mL, clear |
| storage temp. | 2-8°C |
| Application: | TPCA-1 has been used to study its cytotoxic effects in RPMI8226 and LP1 cell lines. It has also been used as a culture media supplement for nuclear protein fractions extracted from human airway smooth muscle cells. |
| Biochem/physiol Actions: | TPCA-1 is a potent and selective inhibitor of human IκB kinase-2 (IKK-2) with IC50 = 17.9 nM for IKK-2 compared to 400nm for IKK-1. It has been used to study inhibition of IKK-2 to prevent inflammatory mediator release in animal models of arthritis and airway inflammation. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 1, 5 mg in glass bottle |
| Preparation Note: | TPCA-1 is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml. It is insoluble in water. |
| Hazard Codes | Xn |
| Risk Statements | 22-36 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Purity | ≥95% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |